111results about "Cationic antimicrobial peptides" patented technology

The invention relates to the field of animal breeding, and discloses a pig beta defensin compound preparation which comprises pig beta defensin PBD1, PBD2 and PBD114, and the weight ratio of the PBD1 to the PBD2 to the PBD114 is 1: 1: 1. The porcine beta defensin PBD1, the porcine beta defensin PBD2 and the porcine beta defensin PBD114 are recombinant proteins, and are respectively expressed in escherichia coli BL21 (DE3) PLysS competent cells by a pET-32a expression vector. Through the synergistic effect of the defensins PBD1, PBD2 and PBD114, the minimum inhibitory concentration (MIC) of the EPEC is reduced to 18.75 mu g / mL from 75 mu g / mL of single defensins, and is reduced by 75%; within 24 hours, the bacteriostasis rate of the compound preparation reaches 90%, and the inhibition effect on EPEC is remarkably improved.

The invention discloses a fusion antibacterial peptide BMAP18-BSN37 and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 1, and the amino acid sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 2. The fusion antibacterial peptide BMAP18-BSN37 gene is inserted into a pNZ8148 expression vector to construct a recombinant expression vector pUBB, so that protein aggregation or degradation in cells can be avoided, and the survival rate of strains and the stability of protein expression are improved. The method comprises the following steps: transferring a plasmid pUBB into a lactic acid bacteria NZ9000 strain through electrotransformation, and screening a recombinant lactic acid bacteria strain capable of expressing a fusion protein BMAP18-BSN37 to obtain a recombinant strain NZ-BB; the recombinant lactic acid bacteria NZ-BB strain shows a remarkable prevention effect in an animal infection model, and can effectively reduce bacterial colonization and relieve pathological injury; the Salmonella strain has the potential of being used as an animal feed additive, can reduce the use of antibiotics and chemicals, slow down the development of bacterial drug resistance, improve animal immunity and slow down intestinal inflammation caused by salmonella, and provides support for effectively preventing the health of livestock and poultry.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. A preferred peptide includes the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. The peptides include the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

The invention relates to an antibacterial peptide CnCATH as well as a coding gene and application thereof, and belongs to the technical field of biomedicine. The novel antibacterial peptide is extracted from sika deer bone marrow, and the amino acid sequence is as shown in SEQ ID NO. 2. The antibacterial peptide shows strong antibacterial activity on various microorganisms including gram-negative bacteria, gram-positive bacteria and fungi, the sterilization speed of the antibacterial peptide is obviously improved compared with that of traditional antibiotics, the bacterial strain is not prone to drug resistance, endotoxin can be further neutralized, and the concentration of the endotoxin can be further reduced. The novel sika deer-derived antibacterial peptide provided by the invention has the advantages of small molecular weight, simple artificial synthesis, low drug resistance tendency and high broad-spectrum bactericidal activity, and provides a new strategy for microbial anti-infection treatment and prevention and treatment of diseases caused by endotoxin.

The invention discloses a porcine beta-defensin-3 gene core promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The sequence of the core promoter is as shown in SEQ ID No.1, and the core promoter has remarkable promoter activity in porcine small intestine epithelial cells and can be regulated and controlled by nutrient substances sodium butyrate and glutamine. The invention also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: carrying out PCR (Polymerase Chain Reaction) amplification by taking porcine small intestine epithelial cell DNA (Deoxyribonucleic Acid) as a template, constructing a pMD-18T-pBD-3-P recombinant plasmid by taking upstream and downstream primers as shown in SEQ No.2-SEQ No.3, and amplifying by taking the recombinant plasmid as a template to obtain a core promoter fragment. The core promoter disclosed by the invention provides an excellent experimental system for researching a transcription regulation mechanism of the porcine beta-defensin-3 gene, the nutritional response characteristic of the core promoter provides a new platform for researching nutrition-immune interaction, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

The invention relates to unique peptide sequences with high antimicrobial activity and stability as well as low hemolytic activity, generated by a unique strategy defined by determining the specific motifs of peptides with high antimicrobial activity in the antimicrobial peptide database by a structure-activity relationship based approach and combining the determined motifs with a localization-based approach taking into account the N-terminal, C-terminal or center position in the peptide.

The invention relates to the technical field of gene engineering, and relates to a construction method of sgRNA with a pBD2 gene knocked out and a construction method of a pig intestine epithelial cell line with the pBD2 gene knocked out. According to a pBD2 gene sequence, sgRNA capable of targeting the gene is designed and synthesized, plasmids of a CRISPR / Cas9 system containing the sgRNA are constructed by using a molecular cloning and recombination technology, the plasmids are transfected into a pig small intestine epithelial cell line, gene editing is performed on a specific position of the pBD2 gene, and a stable monoclonal cell line with the pBD2 gene knocked out is obtained through puromycin drug screening. The homozygous pBD2 gene knockout cell strain obtained by the method is used as a cell model and can be used for exploring the effects of the pBD2 gene in the aspects of immunoregulation, sphingolipid metabolism, cell cycle and the like of small intestine cells.

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The present invention relates to an antimicrobial protein SBL2200 having antimicrobial activity specific for Streptococci and, more specifically, to: a Streptococci-specific antimicrobial protein SBL2200 having the capacity to specifically lyse Streptococci and having an amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Streptococci, comprising the Streptococci-specific antimicrobial protein SBL2200 as an active ingredient.

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration. Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration.SOLUTION: Such formulations provide the theta defensin and / or theta defensin analog in a slightly acidic buffer containing propylene glycol. Surprisingly, the inventors have found that such formulations increase the bioavailability of θ-defensins and / or θ-defensin analogues so provided by at least a factor of 10 compared to conventional isotonic saline solutions, and dramatically improve bioavailability in human subjects compared to animal models. The inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, allowing reduced injection volumes and sterilization by simple filtration.SELECTED DRAWING: Figure 2

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and / or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.

Antimicrobial modified defensin or defensin-like peptides, modified C-terminal fragments of a defensin or defensin-like peptides and nucleic acids encoding the same are disclosed. Compositions comprising the defensin variant peptides and methods of their use to control microbial infections of plants and vertebrate subjects as well as contamination of feedstuffs and foodstuffs are also disclosed.

The present disclosure relates to antibacterial hydrogel compositions comprising a synergistic combination of antimicrobial peptides, and methods and kits for preparing the same.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

The present invention describes a branched peptide of formula (I), the use of the same as an antibacterial, and related pharmaceutical compositions or medical devices.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

Disclosed is an antimicrobial peptide comprising the sequence IGKX1FX2RIVX3RKX4RFLX5X6LVRPLX7 (SEQ ID NO: 7), wherein each of X1, X2, X3, X4, X5, X6, and X7 is an amino acid independently selected from the group consisting of E, K, R, L, I, V, F, A, W, V and P, preferably from the group consisting of E, K, R, L, I, V, F, A, W and V, more preferably from the group consisting of E, K, R, L, W and V. Optionally, one amino acid in this sequence selected from the group of L, V, F, A, I, W, Y or Q, with the exception of X1-X7, is replaced by another amino acid selected from said group or by P. Particularly preferred peptides are IGKEFKRIVERKWRFLRELVRPLR (SEQ ID NO: 2), IGKKFKRIVRRKKRFLRKLVRPLR (SEQ ID NO: 3), IGKEFKRIVERKWRFLRKLVRPLR (SEQ ID NO: 4), IGKEFLRIVERKWRFLRKLVRPLL (SEQ ID NO: 5) and IGKEFLRIVERKWRFLVKLVRPLL (SEQ ID NO: 6).

The invention discloses a composition with immunoregulation and anti-aging functions and a preparation method of the composition. The composition comprises the following core components: marine collagen peptide, fusion polypeptide CPF-1, a monoclonal antibody mAb Senolix targeting aging cells, pentagalloylglucose (PGG) and hericium erinaceus polysaccharide. The fusion polypeptide CPF-1 is designed through a structural domain fusion strategy, and has collagen binding, immune activation and antibacterial functions; the monoclonal antibody mAb Senolix is targeted to a senescent cell surface antigen p16 (INK4a), and senescent cells are cleared through an ADCC effect. Through the synergistic effect of multiple components, the composition significantly improves the activity of immune cells, promotes collagen synthesis and alleviates chronic inflammation, shows excellent immunoregulation and anti-aging effects in an in-vitro cell model and an immunosuppressive mouse model, and can be used for developing immunopotentiators, anti-aging drugs or functional foods.

The invention provides a cationic antibacterial peptide compound preparation, an anti-organic interference compound disinfectant and a preparation method of the cationic antibacterial peptide compound preparation. The cationic antibacterial peptide compound preparation is obtained by culturing fermentation liquor through genetically engineered bacteria, purifying the fermentation liquor and adding a stabilizer. Effective disinfection components of the compound disinfectant resistant to organic interference are prepared by mixing the cationic antibacterial peptide compound preparation with an essential oil emulsifying preparation, a quaternary ammonium salt disinfectant and a guanidine disinfectant according to the mass ratio of the cationic antibacterial peptide compound preparation to the essential oil emulsifying preparation to the quaternary ammonium salt disinfectant to the guanidine disinfectant being (5-8): (4: 6): (4-5): (2-4). The prepared composite disinfectant can solve the problem that the titer of a conventional disinfectant is remarkably reduced in an organic matter highly-polluted environment, and compared with the conventional disinfectant, the composite disinfectant has the advantages that the influence of organic matter interference is remarkably reduced, the safety is high, and the composite disinfectant has a good application prospect.

The present invention provides hepcidin analogs with improved in vivo half-lives, as well as related pharmaceutical compositions and methods of use. The present invention generally relates to hepcidin analog peptides and methods of making and using them. In certain embodiments, the hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention relates to hepcidin peptide analogs comprising one or more peptide subunits, which form a cyclized structure via an intramolecular bond, such as an intramolecular disulfide bond. In certain embodiments, the cyclized structure exhibits increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life when delivered orally compared to hepcidin or conventional hepcidin analogs.

The present invention relates to the fragment-based synthesis of peptides, in particular the peptide LL37. In specific the present invention relates to a method for fragmented solid phase synthesis of an LL37 peptide of SEQ ID NO: 1, or a variant thereof, comprising providing a first fragment of LL37, or a variant thereof, coupled to a first resin solid support by a cleavable linker, providing at least one further side chain protected fragment of LL37 coupled to a second resin solid support, wherein the fragment-resin linker is acid labile, cleaving the further side chain protected fragment(s) from the second solid support without deprotecting the side chains, and sequentially coupling the first and further fragments to produce a peptide of SEQ ID NO: 1, or a variant thereof.

Disclosed herein are PEG-maximin H5 peptide conjugates and methods for using the same in the treatment or prevention of biofilms and biofouling.

The invention discloses a polypeptide and an application of the polypeptide in preparation of antibiotics. The amino acid sequence of the polypeptide is LRDLVCYCRS10 RGCKGRERMN20 GTCRK25. According to the invention, it is found that L-Crp1 tends to form a double alpha-spiral structure in a membrane environment, the double alpha-spiral structure can fully expose alkaline residues, and the double alpha-spiral structure closely interacts with a microbial membrane and mediates membrane permeation of polypeptide, which is the key of the strong bactericidal activity of L-Crp1 to escherichia coli; however, the disordered segment of the C end of the L-Crp1 peptide chain does not participate in the interaction with the membrane, the polypeptide obtained after the segment is cut off still has a complete double-alpha-spiral structure, the bactericidal activity of the polypeptide is equivalent to that of the L-Crp1, but the length of the peptide chain of the polypeptide is shorter than that of the L-Crp1, so that the production cost is greatly reduced (reduced by 30-40%), and the polypeptide has greater application potential than the L-Crp1.

The invention provides a site-specific mutagenesis vector and a use method thereof, and relates to the field of gene engineering in the biotechnological pharmaceutical industry, the vector contains BbsI restriction enzyme cutting sites except for a polyclone region, and site-specific mutagenesis comprises the steps of carrying out base mutation on the BbsI restriction enzyme cutting sites, removing the BbsI sites and keeping amino acid unchanged. According to the invention, a Golden gate method is adopted to construct the multi-copy vector, and a plurality of copies are directly assembled on a system in one step, so that the time is saved, and the tedious steps of multiple times of enzyme digestion and connection are omitted. According to the invention, a multi-copy vector is constructed in vitro, the copy number of the antibacterial peptide is increased, simultaneous expression of each unit is realized, and the expression quantity is improved. Meanwhile, the antibacterial peptide genes are connected in series by adopting a serial connection technology of the antibacterial peptide genes, so that the expression quantity of the antibacterial peptide is improved on the DNA level.

An isolated, non-naturally occurring cell penetrating peptide (CPP) comprising the amino acid sequence: RRSRTARAGRPGRNSSRPSAPR [SEQ ID NO: 1] and sequences having at least 60% similarity to SEQ ID NO: 1.